| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
139,126,000 |
| Market
Cap: |
136.84(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.8871 - $4.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile bluebird bio is a company focused on the pursuit of curative gene therapies for severe genetic diseases. Co. has late-stage clinical and research programs for the treatment of sickle cell disease (SCD), ss-thalassemia and cerebral adrenoleukodystrophy and is developing research to apply new technologies to these and other diseases. Using a proprietary lentiviral vector platform, Co. custom designs each of its therapies to address the underlying cause of disease by introducing a functional copy of a gene to patients' own isolated hematopoietic stem cells. Co. is developing lovotibeglogene autotemcel as a one-time treatment for patients with SCD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
17,438 |
35,533 |
57,514 |
116,582 |
| Total Sell Value |
$26,639 |
$61,294 |
$139,194 |
$443,003 |
| Total People Sold |
3 |
5 |
5 |
9 |
| Total Sell Transactions |
3 |
9 |
12 |
23 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lynch Daniel |
Director |
– • – |
2017-04-27 |
4 |
OE |
$2.09 |
$2,086 |
D/D |
1,000 |
2,400 |
|
- |
|
| Cole Jason |
Chief Legal Officer |
• – – |
2017-04-26 |
4 |
OE |
$22.53 |
$84,488 |
D/D |
3,750 |
15,801 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2017-04-25 |
4 |
AS |
$86.75 |
$173,500 |
D/D |
(2,000) |
1,400 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2017-04-25 |
4 |
OE |
$2.09 |
$4,173 |
D/D |
2,000 |
3,400 |
|
- |
|
| Walsh Jeffrey T. |
Chief Financialand Strategy Of |
• – – |
2017-04-10 |
4 |
AS |
$87.38 |
$109,225 |
D/D |
(1,250) |
27,305 |
|
- |
|
| Walsh Jeffrey T. |
Chief Financialand Strategy Of |
• – – |
2017-04-10 |
4 |
OE |
$5.50 |
$6,876 |
D/D |
1,250 |
28,555 |
|
- |
|
| Sullivan Eric |
Principal Accounting Officer |
• – – |
2017-04-03 |
4 |
A |
$0.00 |
$0 |
I/I |
300 |
300 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2017-04-03 |
4 |
AS |
$90.87 |
$272,683 |
D/D |
(3,000) |
17,177 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2017-04-03 |
4 |
OE |
$2.09 |
$6,270 |
D/D |
3,000 |
20,177 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2017-03-27 |
4 |
AS |
$90.00 |
$90,000 |
D/D |
(1,000) |
1,400 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2017-03-27 |
4 |
OE |
$2.09 |
$2,086 |
D/D |
1,000 |
2,400 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2017-03-24 |
4 |
AS |
$87.10 |
$174,357 |
D/D |
(2,000) |
1,400 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2017-03-24 |
4 |
OE |
$2.09 |
$4,173 |
D/D |
2,000 |
3,400 |
|
- |
|
| Cole Jason |
Chief Legal Officer |
• – – |
2017-03-16 |
4 |
AS |
$100.07 |
$493,366 |
D/D |
(4,930) |
12,051 |
|
- |
|
| Cole Jason |
Chief Legal Officer |
• – – |
2017-03-16 |
4 |
OE |
$22.53 |
$111,073 |
D/D |
4,930 |
16,981 |
|
- |
|
| Sullivan Eric |
Principal Accounting Officer |
• – – |
2017-03-16 |
4 |
AS |
$99.00 |
$40,689 |
D/D |
(411) |
6,466 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2017-03-16 |
4 |
AS |
$100.07 |
$23,718 |
D/D |
(237) |
1,400 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2017-03-16 |
4 |
OE |
$2.09 |
$494 |
D/D |
237 |
1,637 |
|
- |
|
| Walsh Jeffrey T. |
Chief Financialand Strategy Of |
• – – |
2017-03-16 |
4 |
AS |
$100.07 |
$354,563 |
D/D |
(3,543) |
27,305 |
|
- |
|
| Walsh Jeffrey T. |
Chief Financialand Strategy Of |
• – – |
2017-03-16 |
4 |
OE |
$2.09 |
$8,312 |
D/D |
3,543 |
30,848 |
|
- |
|
| Maraganore John |
Director |
– • – |
2017-03-03 |
4 |
S |
$85.02 |
$1,176,646 |
D/D |
(13,839) |
4,843 |
|
- |
|
| Maraganore John |
Director |
– • – |
2017-03-03 |
4 |
OE |
$0.95 |
$71,923 |
D/D |
13,839 |
18,682 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2017-02-24 |
4 |
AS |
$77.37 |
$157,365 |
D/D |
(2,000) |
1,400 |
|
- |
|
| Lynch Daniel |
Director |
– • – |
2017-02-24 |
4 |
OE |
$2.09 |
$4,173 |
D/D |
2,000 |
3,400 |
|
- |
|
| Mandell James |
Director |
– • – |
2017-02-15 |
4 |
AS |
$80.22 |
$84,235 |
D/D |
(1,050) |
1,000 |
|
- |
|
939 Records found
|
|
Page 23 of 38 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (1.31%) 
